We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for leniolisib (Ballia Holdings Pty Ltd)
Active ingredients
leniolisib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age or older
Therapeutic area
Immunology